The EuroSIDA network 2000-200: Clinical and Virological Outcome of European Patients Infected with HIV
Summary:
The primary objective of the EuroSIDA study is to collect demographic, clinical,
therapeutic and laboratory data on patients with HIV infection to determine the
long-term virological and clinical outcome for patients from Europe. This
knowledge will also be analysed, discussed and presented within the scientific
community to assist physicians and public health officials.
Problem:
Despite recent improvement in the prognosis of HIV-infected patients from
across Europe due to the use of powerful combination antiretroviral therapies,
challenges persist in relation to the durability of responses and new
co-morbidities. These challenges mainly concern development of resistance to
existing treatments and coping with adverse drug reactions. In addition, there
is a dramatic progression in the HIV epidemic in Eastern European countries
requiring development of treatment strategies in this setting.
Aim:
The aim of this project is to continue a long-term, prospective collection of
clinical, laboratory and therapeutic data as well as plasma on a large cohort of
consecutive-HIV-infected patients from across Europe. This in order to assess
the factors associated with the clinical, immunological and virological course
of HIV infection, including the effect and toxicity of antiretroviral agents and
other therapeutic interventions.
There will be a continuation of providing and developing a surveillance
system to describe temporal changes and regional differences in the clinical
course of HIV. These include:
1) the overall pattern of HIV-related diseases and death, and the emergence
of new diseases, including drug-related diseases
2) the prevalence of patients with severe immunosuppression and high viral
replication
3) the virological response to initial antiretroviral therapy.
Expected results:
- Long-term prospective follow-up on 10 900 unselected patients from 70
clinical centres in 26 European countries, providing 40 500 person-years of
follow-up.
- The EuroSIDA main database will serve as a tool to study the course and
evolution of chronic HIV infection in patients from across Europe in the future.
- The study will collect extensive information on adverse events, including
risk factors for, and the occurrence of, cardiovascular disease events.
- In 1999, Poland, the Czech Republic and Hungary entered EuroSIDA. Additional
recruitment from the Newly Associated States in the eastern part of Europe
(Slovakia, Estonia, Latvia, Lithuania, Romania and Ukraine) will continue in
2002 and 2004.
- A central plasma repository of 27 000 samples will allow laboratory analyses
related to HIV resistance and HIV sub-typing.
Potential applications:
The results are widely disseminated by publications in peer-reviewed journals
and are used by health authorities to formulate treatment guidelines. Findings
related to the objectives listed above provide important knowledge for
decision-making in clinical practice in the care of HIV patients.
Partners:
| Nº |
Principal
Scientific
Participants |
Official Address |
Other Information |
| 2 | Schlomo Staszewski | J.W.Goethe University Hospital
Zentrum der Inneren Medizin
Infektionsambulanz/ Medizinsche Klinik III/Haus 68
Theodor-Stern-Kai 7
DE-60590 Frankfurt am Main
Germany | Tel: +49 696 3017688
Fax: +49 696 3016051
E-mail: staszewski@em.uni-frankfurt.de |
| 3 | Christoph Manegold | Bernhard Nocht Institute for
Tropical Medicine, Clinical Department
Bernhard Nocht Strasse 74
DE-20359 Hamburg
Germany | Tel: +49 40 42818370
Fax: +49 40 42818394
E-mail: manegold@bni.uni-hamburg.de |
| 4 | Anne Johnson | Royal Free and U.C. Med. School
Department of Primary Care and Population Sciences
Royal Free Campus
Rowland Hill Street
UK-NW3 2 PF London
United Kingdom | Tel: 44 20 7472 6754
Fax: +44 20 7794 1224
E-mail: a.johnson@pcps.ucl.ac.uk |
| 5 | Peter Reiss | Academisch Ziekenhuis bij de
Universiteit van Amsterdam
Building T, Room T0-123
Meibergdreef 9
NL-1105 AZ Amsterdam
The Netherlands | Tel: +31 2 0566 4479
Fax: +31 2 0691 8821
E-mail: p.reiss@amc.uva.nl |
| 6 | Nathan Clumeck | CHU Saint-Pierre
Department of Infectious Diseases (PL5)
322, rue Haute
BE-1000 Brussels
Belgium | Tel: +32 2 535 4131
Fax: +32 2 539 3614
E-mail: ID-HIV-RESEARCH@stpierre-bru.be |
| 7 | Christine Katlama | Hopital de la Pitié-Salpêtriére
Dept de Medicine Tropicale
Boulevard de l'Hopital 83
FR-75013 Paris, Cedex 13
France | Tel: +33 1 42 16 01 30
Fax: +33 1 42 16 01 26
E-mail: christine.katlama@psl.ap-hop-paris.fr |
| 8 | Antonio Chiesi | Istituto Superiore di Sanità
Laboratory of Virology
Viale Regina Elena, 299
IT-00161 Rome
Italy | Tel: +39 06 4990 3304
Fax: +39 06 4990 2012
E-mail: terapiaantivirale@interbusiness.it |
| 9 | Jose M. Gatell | Hospital Clínic de Barcelona
Unidad de Enfermedades Infecciosas
Villaroel, 170
ES-08 036 Barcelona
Spain | Tel: +34 9 3227 5430
Fax: +34 9 3451 4438
E-mail: Gatell@medicina.ub.es |
| 10 | Andrzej Horban | Wojewodzki Szpital Zakazny
Centrum Diagnostyki i Terapii AIDS
Wolska st. 37
PL-01-201Warszaw
Poland | Tel: +48 22 632 0611
Fax: +48 22 335 5335
E-mail: ahorban@cdit-aids.med.pl |
